Eli Lilly has announced the FDA AdComm Hearing Date for Donanemab.

Published Date: 09 May 2024

The phase 3 TRAILBLAZER-ALZ 2 trial, a large-scale investigation that evaluated the safety and effectiveness of donanemab in patients with early-stage Alzheimer disease over an 18-month period, will be discussed by the FDA AdComm.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Scientists call into question safety of potential new anticancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot